2) We also assessed the activity of metalloproteinases


2). We also assessed the activity of metalloproteinases

MMP2 and MMP9 by gelatin zymography. We found that losartan-M6PHSA did not modify MMP2 and MMP9 activity in bile duct-ligated rats (Fig. 5C). Also, we explored the hepatic expression of transforming Ivacaftor cost growth factor β1 (TGF-β1), a cytokine that mediates the fibrogenic actions of angiotensin II.22 Bile duct ligated rats showed increased TGF-β1 gene expression, which was not reduced in rats treated with losartan-M6PHSA (Fig. 5E). Further studies should analyze protein expression of TGF-β1 to confirm these results. Furthermore, we explored whether losartan-M6PHSA reduces hepatic inflammation. First, we analyzed in HSCs the expression of proinflammatory genes (ICAM-1 and interleukin-8 [IL-8]). Both genes were up-regulated by angiotensin II treatment. Treatment by losartan and losartan-M6HSA reduced this effect (Fig. 6A,B). Next, in vivo liver inflammation was assessed by quantifying the infiltration of inflammatory cells (CD43-positive) in the hepatic parenchyma by immunohistochemistry. Compared to sham-operated rats, bile duct–ligated rats showed a marked increase in the infiltration of CD43-positive inflammatory cells (Fig. 7A). This effect was blunted by treatment

with losartan-M6HSA and, to a lesser extent, by oral losartan. find more In contrast, monocyte chemotactic protein 1 expression was not modified by any of the treatments (Fig. 7C). The number of CD43-positive cells was also decreased in CCl4-treated rats (Fig. 7B). This study demonstrates that advanced liver fibrosis can be attenuated by short-term administration of an antifibrotic drug selectively targeted to activated HSCs. We provide evidence that the delivery of the AT1 receptor blocker losartan to activated HSCs reduces hepatic inflammation and collagen deposition. This RVX-208 novel approach appears to be more effective than conventional treatment with oral losartan. The new drug conjugate losartan-M6PHSA was successfully synthesized by applying a novel linker system that binds losartan via a transition-metal coordination bond. Traditionally, linking

drugs to carrier moieties represents a complex issue involving tedious drug-derivatization reaction steps.23 A key property of our platinum linker, ULS, is that it can be applied for conjugation of many valuable drug molecules containing aromatic nitrogens, forming a bond of intermediate binding strength. The ligand-exchange behavior of platinum compounds is quite slow, giving them a high kinetic stability.24 The slow rate of drug release from the linker11, 15 will cause sustained drug release within target cells and will effectuate only very low concentrations of reactive platinum in target cells, which are orders of magnitude lower than applied in cisplatin cancer therapy. One therefore would predict rapid detoxification of ULS by binding to cytosolic platinophilic ligands.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>